Autor: |
Emilio Alfonso, Francesca Giordana, José María García Acuña, Alberto Garay, Jorge F. Saucedo, Danielle A. Southern, Tetsuma Kawaji, Paolo Vadalà, Oliver Kalpak, Yan Yan, Xiantao Song, Sasko Kedev, Masa-aki Kawashiri, Yuji Ikari, José Ramón González-Juanatey, Claudio Moretti, Stephen B. Wilton, Wouter J. Kikkert, Helge Möllmann, Ioanna Xanthopoulou, Michal Kowara, Yalei Chen, Xiao Wang, Iván J. Núñez-Gil, Kenji Sakata, Belén Terol, Toshiharu Fujii, Jing-Yao Fan, Zenon Huczek, Masakazu Yamagishi, Luis C. L. Correia, Shaoping Nie, Christoph Liebetrau, Fabrizio D'Ascenzo, Dimitrios Alexopoulos, Hiroki Shiomi, Dongfeng Zhang, Sergio Raposeiras Roubín, Patrizia Noussan, José P.S. Henriques, Fiorenzo Gaita, Mario Iannaccone, Emad Abu Assi, Roberto Garbo, Krzysztof J. Filipiak, Albert Ariza-Solé, Neriman Osman, Francesco Colombo, Takuya Nakahashi |
Přispěvatelé: |
ACS - Atherosclerosis & ischemic syndromes, Cardiology |
Jazyk: |
angličtina |
Rok vydání: |
2018 |
Předmět: |
|
Zdroj: |
European heart journal. Acute cardiovascular care, 7(7), 631-638. SAGE Publications Ltd |
ISSN: |
2048-8726 |
Popis: |
Background: The prevalence and outcome of patients with cancer that experience acute coronary syndrome (ACS) have to be determined. Methods and results: The BleeMACS project is a multicentre observational registry enrolling patients with acute coronary syndrome undergoing percutaneous coronary intervention worldwide in 15 hospitals. The primary endpoint was a composite event of death and re-infarction after one year of follow-up. Bleedings were the secondary endpoint. 15,401 patients were enrolled, 926 (6.4%) in the cancer group and 14,475 (93.6%) in the group of patients without cancer. Patients with cancer were older (70.8±10.3 vs. 62.8±12.1 years, PConclusion: Cancer has a non-negligible prevalence in patients with acute coronary syndrome undergoing percutaneous coronary intervention, with a major risk of cardiovascular events and bleedings. Moreover, these patients are often undertreated from clinical despite medical therapy seems to be protective. Registration:The BleeMACS project (NCT02466854). |
Databáze: |
OpenAIRE |
Externí odkaz: |
|